Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Free Cash Flow (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Free Cash Flow for 7 consecutive years, with -$14.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 36.21% to -$14.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$55.8 million, a 216.32% decrease, with the full-year FY2025 number at -$51.8 million, up 24.66% from a year prior.
  • Free Cash Flow was -$14.9 million for Q4 2025 at Outlook Therapeutics, down from -$12.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$11.0 million in Q4 2024 to a low of -$16.6 million in Q1 2025.